Pharmaceutical
Home » Chemotherapy Induced Nausea And Vomiting Treatment Market

Chemotherapy Induced Nausea And Vomiting Treatment Market

Chemotherapy Induced Nausea And Vomiting Treatment Market By Drug Class (Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine, Others) – Growth, Share, Opportunities & Competitive Analysis, 2018 – 2026
Report Book

Published Date: Aug. 2018
Category: Pharmaceuticals
Report ID: 59261
Report Format: PDF
No of Pages: 190

Rating: Credence Reports

Market Insights

Chemotherapy-induced nausea and vomiting treatment market are expected to reach US$ 3,626.1 million by 2026, up from US$ 2,057.4 million in 2017, with a compound annual growth rate (CAGR) of 6.5% from 2018 to 2026. As per the latest statistics provided by the National Cancer Institute, in 2018, approximately 1,735,350 new cancer cases will be reported, with an estimated 609,640 people dying from cancer. Technological advancements in diagnostic kits have resulted in early cancer diagnosis, allowing the physician to immediately enroll the patient in chemotherapeutic treatment. It is important to understand that 90% of patients receiving chemotherapy suffer from nausea and vomiting.

There has been a shift in the treatment regimen; earlier, dopamine antagonists in combination with corticosteroids were prescribed as antiemetic agents, which have been replaced by a drug combination of serotonin receptor antagonists and NK1 receptor antagonists. The rising prevalence of cancer and the growing popularity of chemotherapy as a treatment option are responsible for the dominance of North America in the CINV treatment market. Developing healthcare infrastructure and competition exerted by local generic drug manufacturers stimulate the CINV market’s growth in Asia Pacific.

Market Synopsis

Excellent pharmacokinetic properties will boost the sale of NK1 receptor antagonists during the forecast period.

Serotonin receptor antagonists are leading the drug-class market for chemotherapy-induced nausea and vomiting treatment on account of their excellent antiemetic activity in cancer patients suffering from acute nausea. Drugs such as palonosetron, granisetron, and dolasetron are available as oral, parenteral, and transdermal patches, catering to the needs of patients of all ages. Multiple clinical trials have shown that combining dopamine antagonists with benzodiazepines or corticosteroids are effective in treating patients with refractory CINV. NK1 receptor antagonists have shown excellent clinical outcomes in the treatment of delayed nausea with excellent pharmacokinetic properties. They are prescribed in combination with 5HT3 receptor antagonists, e.g., Alkynzeo (Helsinki Healthcare), and are set to register tremendous growth during the forecast period.

An increasing number of patients seeking chemotherapy will drive the CINV treatment market in North America.

North America is currently leading chemotherapy-induced nausea and vomiting treatment market with 38% of the regional market. The rising prevalence of patients suffering from cancer and the growing popularity of chemotherapy as a treatment option among the patient population drive the CINV market in North America. Major players such as Sanofi-Aventis and Helsinn Healthcare are striving to manufacture effective antiemetic drugs to treat CINV in North America. The existence of a well-developed healthcare infrastructure and adherence to treatment guidelines steer the CINV market in Europe. The competition exerted by local players manufacturing generic drugs, as well as a favorable regulatory environment, drive the Asia Pacific CINV market growth. Latin America, the Middle East, and Africa serve as lucrative markets due to rising awareness of chemotherapy-induced nausea and vomiting among healthcare professionals and a rise in per capita income.

Periods of History and Forecast

This research report presents the analysis of each segment from 2016 to 2026, considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

The quantitative analysis for the report on chemotherapy-induced nausea and vomiting treatment market is postulated on the basis of the latest market trends. The market is further segmented by drug class and geography.

The latest market trends and quantitative analysis are performed to understand the market dynamics existing in chemotherapy-induced nausea and vomiting treatment market. This report emphasizes critical information about inorganic business strategies such as mergers and collaboration between pharmaceutical players. In the product portfolio section, quick insight regarding the diverse brands in different drug combinations is obtained. The major players dominating chemotherapy-induced nausea and vomiting treatment market are Baxter Pharmaceuticals, Eisai, Inc., Helsinn Healthcare, GlaxoSmithKline, Plc, Merck & Co., Inc., ProStrakan, Inc., Pfizer, Inc., Sanofi-Aventis, Solvay Pharmaceuticals, Inc., and Teva Pharmaceutical Industries Ltd.

Key questions are answered in this report.

  • Who are the leading players in chemotherapy-induced nausea and vomiting treatment market?
  • What will be the performance of the CINV market during the forecast period from 2018 to 2026?
  • What are the latest market trends in the CINV treatment market?
  • What are the drivers and challenges facing the CINV treatment market?
  • What is the pathophysiology that triggers chemotherapy-induced nausea and vomiting?
  • What are the treatment guidelines adopted by healthcare professionals throughout the globe?
  • Which is the leading and fastest-growing drug class segment for the CINV treatment market?
  • Which is the leading and fastest-growing regional segment for the CINV treatment market?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global CINVT Market Portraiture
2.2. Global CINVT Market, by Class, 2017 (US$ Mn)
2.3. Global CINVT Market, by Geography, 2017 (US$ Mn)

Chapter 3. Chemotherapy Induced Nausea and Vomiting Treatment (CINVT) Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global CINVT Market, by Key Players, 2017

Chapter 4. Global Chemotherapy Induced Nausea and Vomiting Treatment (CINVT) Market, by Drug Class
4.1. Overview
4.2. Serotonin Receptor Antagonist
4.2.1. Ondansetron
4.2.2. Granisetron
4.2.3. Dolasetron
4.2.4. Palonosetron
4.3. Neurokinin NK1 Receptor Antagonist
4.3.1. Aprepitant
4.3.2. Casopitant
4.3.3. Netupitant
4.4. Dopamine Antagonist
4.4.1. Metoclopramide
4.4.2. Prochlorperazine
4.5. Benzodiazepine
4.5.1. Lorazepam
4.6. Others (Corticosteroids, Cannabinoids)

Chapter 5. Global Chemotherapy Induced Nausea and Vomiting Treatment (CINVT) Market, by Geography
5.1. Overview
5.2. North America CINVT Market Analysis, 2016 – 2026
5.2.1. North America CINVT Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.2.2. North America CINVT Market, by Country, 2016 – 2026 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe CINVT Market Analysis, 2016 – 2026
5.3.1. Europe CINVT Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.3.2. Europe CINVT Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market Analysis, 2016 – 2026
5.4.1. Asia Pacific CINVT Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.4.2. Asia Pacific CINVT Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of Asia Pacific
5.5. Latin America CINVT Market Analysis, 2016 – 2026
5.5.1. Latin America CINVT Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.5.2. Latin America CINVT Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa CINVT Market Analysis, 2016 – 2026
5.6.1. MEA CINVT Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.6.2. MEA CINVT Market, by Region, 2016 – 2026 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA

Chapter 6. Company Profiles
6.1. Baxter Pharmaceuticals
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Eisai, Inc.
6.3. Helsinn Healthcare
6.4. GlaxoSmithkline, Plc
6.5. Merck & Co. Inc.
6.6. ProStrakan, Inc.
6.7. Pfizer, Inc.
6.8. Sanofi-Aventis
6.9. Solvay Pharmaceuticals, Inc.
6.10. Teva Pharmaceutical Industries Ltd.

List of Figures

FIG. 1 Chemotherapy Induced Nausea and Vomiting Treatment (CINVT) Market: Research Methodology
FIG. 2 CINVT Market Segmentation
FIG. 3 Global CINVT Market, by Drug Class, 2017 (US$ Mn)
FIG. 4 Global CINVT Market, by Geography, 2017 (US$ Mn)
FIG. 5 Attractive Investment Proposition: by Geography, 2017
FIG. 6 Competitive Analysis: Global CINVT Market, by Key Players, 2017
FIG. 7 Global Ondansetron Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 8 Global Granisetron Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 9 Global Dolasetron Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 10 Global Palonosetron Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 11 Global Aprepitant Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 12 Global Casopitant Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 13 Global Netupitant Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 14 Global Metoclopramide Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 15 Global Prochlorperazine Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 16 Global Lorazepam Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 17 Global Other Drug Class Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 18 U.S. Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 19 Canada Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 20 U.K. Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 21 Germany Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 22 Rest of Europe Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 23 China Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 24 Japan Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 25 Rest of Asia Pacific Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 26 Brazil Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 27 Mexico Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 28 Rest of Latin America Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 29 GCC Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 30 Rest of Middle East and Africa Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)

List of Tables

TABLE 1 Global Chemotherapy Induced Nausea and Vomiting Treatment (CINVT) Market Portraiture
TABLE 2 Global CINVT Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 3 Global Serotonin Receptor Antagonist Market for Chemotherapy Induced Nausea and Vomiting Treatment, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 4 Global Neurokinin NK1 Receptor Antagonist Market for Chemotherapy Induced Nausea and Vomiting Treatment, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 5 Global Dopamine Antagonist Market for Chemotherapy Induced Nausea and Vomiting Treatment, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 6 Global Benzodiazepine Antagonist Market for Chemotherapy Induced Nausea and Vomiting Treatment, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 7 Global CINVT Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 8 North America CINVT Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 9 North America CINVT Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 10 Europe CINVT Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 11 Europe CINVT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 12 Asia Pacific CINVT Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 13 Asia Pacific CINVT Market, by Country/Region, 2015 – 2025 (US$ Mn)
TABLE 14 Latin America CINVT Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 15 Latin America CINVT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 16 Middle East and Africa CINVT Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 17 Middle East and Africa CINVT Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 18 Baxter Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 19 Eisai, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 20 Helsinn Healthcare: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 GlaxoSmithkline, Plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 ProStrakan, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 25 Sanofi-Aventis: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 26 Solvay Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 27 Teva Pharmaceutical Industries Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Frequently Asked Question

What is the size of Chemotherapy Induced Nausea And Vomiting Treatment Market?

The market for Chemotherapy Induced Nausea And Vomiting Treatment Market is expected to reach USD$ 2,057.4 Mn in 2026.

What is the Chemotherapy Induced Nausea And Vomiting Treatment Market CAGR?

The Chemotherapy Induced Nausea And Vomiting Treatment Market is expected to see significant CAGR growth over the coming years, at 6.5%.

What is the Forecast period considered for Chemotherapy Induced Nausea And Vomiting Treatment Market?

The report is forecasted from 2018 -2026.

What is the base year considered for Chemotherapy Induced Nausea And Vomiting Treatment Market?

The base year of this report is 2017.

Who are the major players in this market?

Baxter Pharmaceuticals, Eisai, Inc., Helsinn Healthcare, GlaxoSmithKline, Plc, Merck & Co., Inc., ProStrakan, Inc., Pfizer, Inc., Sanofi-Aventis, Solvay Pharmaceuticals, Inc. are some of the major players in the global market.

Healthcare

Trientine Hydrochloride Market

Published Date: Sept 2023
Category: Healthcare
Report ID: 58081
Report Format: PDF
No of Pages: 247

Pharmaceutical

Pharmaceutical Chemicals Market

Published Date: Sept 2023
Category: Pharmaceuticals
Report ID: 62118
Report Format: PDF
No of Pages: 247

Pharmaceutical

Wilson’s Disease Drugs Market

Published Date: Sept 2023
Category: Pharmaceuticals
Report ID: 58947
Report Format: PDF
No of Pages: 190

Healthcare

Stretch Marks Treatment Market

Published Date: Sept 2023
Category: Healthcare
Report ID: 62116
Report Format: PDF
No of Pages: 221

Pharmaceutical

Fetal Bovine Serum Market

Published Date: Sept 2023
Category: Pharmaceuticals
Report ID: 62115
Report Format: PDF
No of Pages: 238

Healthcare

Cirrhosis Market

Published Date: Sept 2023
Category: Healthcare
Report ID: 62114
Report Format: PDF
No of Pages: 229

Pharmaceutical

Congenital Hyperinsulinism Treatment Market

Published Date: Sept 2023
Category: Pharmaceuticals
Report ID: 62113
Report Format: PDF
No of Pages: 219

Healthcare

Cryptococcal Meningitis Treatment Market

Published Date: Sept 2023
Category: Healthcare
Report ID: 62112
Report Format: PDF
No of Pages: 237

Healthcare

Dermatology Endoscopy devices Market

Published Date: Sept 2023
Category: Healthcare
Report ID: 62111
Report Format: PDF
No of Pages: 237

Healthcare

Cementless Total Knee Arthroplasty Market

Published Date: Sept 2023
Category: Healthcare
Report ID: 62110
Report Format: PDF
No of Pages: 228

Healthcare

Cell & Gene Therapy Clinical Trials Market

Published Date: Sept 2023
Category: Healthcare
Report ID: 62109
Report Format: PDF
No of Pages: 228

HealthCare

Self-sampling Blood Collection and Storage Device Market

Published Date: Sept 2023
Category: Healthcare
Report ID: 61352
Report Format: PDF
No of Pages: 234

Download Sample Report


Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN
WhatsApp Now